vs
ALERUS FINANCIAL CORP（ALRS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ALERUS FINANCIAL CORP的季度营收约是REGENXBIO Inc.的1.5倍（$45.2M vs $30.3M），ALERUS FINANCIAL CORP净利率更高（-73.2% vs -221.3%，领先148.2%），REGENXBIO Inc.同比增速更快（43.0% vs 18.0%），ALERUS FINANCIAL CORP自由现金流更多（$58.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -2.5%）
阿勒鲁斯金融公司（品牌简称Alerus）是一家连锁金融机构，总部位于北达科他州大福克斯，网点分布在北达科他、明尼苏达、威斯康星与亚利桑那州，为客户提供银行、抵押贷款、财富管理以及退休规划等多种金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ALRS vs RGNX — 直观对比
营收规模更大
ALRS
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出25.0%
18.0%
净利率更高
ALRS
高出148.2%
-221.3%
自由现金流更多
ALRS
多$111.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.2M | $30.3M |
| 净利润 | $-33.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -96.0% | -190.0% |
| 净利率 | -73.2% | -221.3% |
| 营收同比 | 18.0% | 43.0% |
| 净利润同比 | -49232.8% | -31.2% |
| 每股收益（稀释后） | $-1.27 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALRSRGNX
| Q4 25 | $45.2M | $30.3M | ||
| Q3 25 | $72.6M | $29.7M | ||
| Q2 25 | $74.8M | $21.4M | ||
| Q1 25 | $68.8M | $89.0M | ||
| Q4 24 | $72.2M | $21.2M | ||
| Q3 24 | $50.9M | $24.2M | ||
| Q2 24 | $51.4M | $22.3M | ||
| Q1 24 | $47.5M | $15.6M |
净利润ALRSRGNX
| Q4 25 | $-33.1M | $-67.1M | ||
| Q3 25 | $16.9M | $-61.9M | ||
| Q2 25 | $20.3M | $-70.9M | ||
| Q1 25 | $13.3M | $6.1M | ||
| Q4 24 | $-67.0K | $-51.2M | ||
| Q3 24 | $5.2M | $-59.6M | ||
| Q2 24 | $6.2M | $-53.0M | ||
| Q1 24 | $6.4M | $-63.3M |
毛利率ALRSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ALRSRGNX
| Q4 25 | -96.0% | -190.0% | ||
| Q3 25 | 30.4% | -176.3% | ||
| Q2 25 | 35.2% | -296.3% | ||
| Q1 25 | 25.5% | 13.6% | ||
| Q4 24 | -0.8% | -242.1% | ||
| Q3 24 | 13.4% | -256.6% | ||
| Q2 24 | 15.8% | -251.3% | ||
| Q1 24 | 17.9% | -408.8% |
净利率ALRSRGNX
| Q4 25 | -73.2% | -221.3% | ||
| Q3 25 | 23.3% | -208.3% | ||
| Q2 25 | 27.1% | -331.8% | ||
| Q1 25 | 19.4% | 6.8% | ||
| Q4 24 | -0.2% | -241.3% | ||
| Q3 24 | 10.2% | -246.3% | ||
| Q2 24 | 12.1% | -237.7% | ||
| Q1 24 | 13.5% | -405.4% |
每股收益（稀释后）ALRSRGNX
| Q4 25 | $-1.27 | $-1.30 | ||
| Q3 25 | $0.65 | $-1.20 | ||
| Q2 25 | $0.78 | $-1.38 | ||
| Q1 25 | $0.52 | $0.12 | ||
| Q4 24 | $-0.06 | $-0.99 | ||
| Q3 24 | $0.26 | $-1.17 | ||
| Q2 24 | $0.31 | $-1.05 | ||
| Q1 24 | $0.32 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $67.2M | $230.1M |
| 总债务越低越好 | $59.2M | — |
| 股东权益账面价值 | $564.9M | $102.7M |
| 总资产 | $5.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
现金及短期投资ALRSRGNX
| Q4 25 | $67.2M | $230.1M | ||
| Q3 25 | $92.0M | $274.2M | ||
| Q2 25 | $80.9M | $323.3M | ||
| Q1 25 | $83.0M | $267.9M | ||
| Q4 24 | $61.2M | $234.7M | ||
| Q3 24 | $66.0M | $255.5M | ||
| Q2 24 | $438.1M | $290.4M | ||
| Q1 24 | $545.8M | $338.7M |
总债务ALRSRGNX
| Q4 25 | $59.2M | — | ||
| Q3 25 | $59.2M | — | ||
| Q2 25 | $59.1M | — | ||
| Q1 25 | $59.1M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $59.0M | — | ||
| Q2 24 | $59.0M | — | ||
| Q1 24 | $59.0M | — |
股东权益ALRSRGNX
| Q4 25 | $564.9M | $102.7M | ||
| Q3 25 | $550.7M | $161.5M | ||
| Q2 25 | $533.2M | $213.7M | ||
| Q1 25 | $514.2M | $274.2M | ||
| Q4 24 | $495.4M | $259.7M | ||
| Q3 24 | $386.5M | $301.4M | ||
| Q2 24 | $373.2M | $348.3M | ||
| Q1 24 | $371.6M | $390.7M |
总资产ALRSRGNX
| Q4 25 | $5.2B | $453.0M | ||
| Q3 25 | $5.3B | $525.2M | ||
| Q2 25 | $5.3B | $581.0M | ||
| Q1 25 | $5.3B | $490.9M | ||
| Q4 24 | $5.3B | $466.0M | ||
| Q3 24 | $4.4B | $519.1M | ||
| Q2 24 | $4.4B | $569.4M | ||
| Q1 24 | $4.3B | $629.2M |
负债/权益比ALRSRGNX
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.11× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $58.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 130.2% | -174.0% |
| 资本支出强度资本支出/营收 | 19.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $102.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ALRSRGNX
| Q4 25 | $67.5M | $-52.3M | ||
| Q3 25 | $32.8M | $-56.0M | ||
| Q2 25 | $10.7M | $-49.3M | ||
| Q1 25 | $7.7M | $33.6M | ||
| Q4 24 | $21.7M | $-31.6M | ||
| Q3 24 | $20.2M | $-40.5M | ||
| Q2 24 | $-12.5M | $-45.5M | ||
| Q1 24 | $11.7M | $-55.5M |
自由现金流ALRSRGNX
| Q4 25 | $58.8M | $-52.8M | ||
| Q3 25 | $30.3M | $-56.5M | ||
| Q2 25 | $7.6M | $-49.7M | ||
| Q1 25 | $5.7M | $32.6M | ||
| Q4 24 | $9.4M | $-32.7M | ||
| Q3 24 | $17.4M | $-40.9M | ||
| Q2 24 | $-16.1M | $-46.0M | ||
| Q1 24 | $10.8M | $-56.0M |
自由现金流率ALRSRGNX
| Q4 25 | 130.2% | -174.0% | ||
| Q3 25 | 41.8% | -189.9% | ||
| Q2 25 | 10.1% | -232.8% | ||
| Q1 25 | 8.2% | 36.6% | ||
| Q4 24 | 13.0% | -154.2% | ||
| Q3 24 | 34.2% | -168.9% | ||
| Q2 24 | -31.4% | -206.2% | ||
| Q1 24 | 22.8% | -358.5% |
资本支出强度ALRSRGNX
| Q4 25 | 19.3% | 1.7% | ||
| Q3 25 | 3.4% | 1.7% | ||
| Q2 25 | 4.2% | 1.8% | ||
| Q1 25 | 3.0% | 1.2% | ||
| Q4 24 | 17.1% | 5.1% | ||
| Q3 24 | 5.4% | 1.3% | ||
| Q2 24 | 7.2% | 2.1% | ||
| Q1 24 | 1.9% | 3.6% |
现金转化率ALRSRGNX
| Q4 25 | — | — | ||
| Q3 25 | 1.94× | — | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | 0.58× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.88× | — | ||
| Q2 24 | -2.01× | — | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALRS
| Other | $17.3M | 38% |
| Retirement And Benefit Services | $17.3M | 38% |
| Wealth Management | $7.4M | 16% |
| Mortgage Banking | $3.2M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
